Yili Pharma raises nearly RMB 400m Series A for radiopharma Huagai Capital leads a sizable A round for a China radiopharma company pushing candidates toward the clinic.
Abbisko’s pimicotinib wins FDA approval for TGCT China-origin CSF-1R inhibitor cleared in the U.S. after NMPA, Canada, and Switzerland—Merck KGaA holds global rights.
